SCHEMBL18974079

SCHEMBL18974079

CCOCOc1ccc(C2(c3ccc(OCC4CO4)cc3)CCCCC2)cc1

nearest known ligand 0.46

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ ALDH1A1 P00352 5/20 0.46
▸ TSHR P16473 4/20 0.46
▸ TP53 P04637 3/20 0.46
▸ MEN1 O00255 3/20 0.46
▸ KMT2A Q03164 3/20 0.46
▸ MAPT P10636 2/20 0.46
▸ HPGD P15428 2/20 0.46
▸ HIF1A Q16665 2/20 0.46
▸ CYP1A2 P05177 1/20 0.46
▸ PPARG P37231 1/20 0.46
▸ TDP1 Q9NUW8 1/20 0.44
▸ PKM P14618 2/20 0.43
▸ LMNA P02545 1/20 0.43
▸ GAA P10253 1/20 0.43
▸ PSMB1 P20618 1/20 0.42
▸ PSMB5 P28074 1/20 0.42
▸ PSMB2 P49721 1/20 0.42
▸ SMN1; SMN2 Q16637 2/20 0.40
▸ CYP3A4 P08684 1/20 0.40
▸ ADORA3 P0DMS8 1/20 0.39

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL26870955 0.93 ALDH1A1 (0.49) ALDH1A1TSHRTP53MEN1KMT2A
SCHEMBL24394464 0.89 TDP1 (0.54) ALDH1A1TSHRTP53MEN1KMT2A
SCHEMBL14969345 0.89 TDP1 (0.54) ALDH1A1TSHRTP53MEN1KMT2A
SCHEMBL5598711 0.89 TDP1 (0.54) ALDH1A1TSHRTP53MEN1KMT2A
SCHEMBL18230814 0.85 PKM (0.57) ALDH1A1TSHRTP53MEN1KMT2A
SCHEMBL13385083 0.82 ALDH1A1 (0.46) ALDH1A1TSHRTP53MEN1KMT2A
SCHEMBL26870931 0.82 TDP1 (0.59) ALDH1A1TSHRTP53MEN1KMT2A
SCHEMBL18230811 0.81 HPGD (0.42) ALDH1A1TSHRTP53MEN1KMT2A
SCHEMBL18535693 0.81 ALDH1A1 (0.55) ALDH1A1TSHRTP53MEN1KMT2A
SCHEMBL20727163 0.81 ALDH1A1 (0.55) ALDH1A1TSHRTP53MEN1KMT2A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2521707-B1 BISPHENOL DERIVATIVES AND THEIR USE AS ANDROGEN RECEPTOR ACTIVITY MODULATORS BRITISH COLUMBIA CANCER AGENCY BRANCH (CA) 2017-06-14 — — EP disclosed
Send feedback